Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings.

摘要: There are several treatment options for patients with metastatic colorectal cancer (mCRC), including those disease that has progressed after chemotherapy. Bevacizumab-containing regimens show good efficacy in previously treated disease. Compared infused 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4), overall survival progression-free significantly longer FOLFOX-4 combination bevacizumab as second-line advanced or mCRC. In addition, the response rates time to progression greater of bevacizumab, cetuximab, irinotecan irinotecan-refractory mCRC compared cetuximab therapy. This is well tolerated, no additive toxicities reported. The role refractory irinotecan, less clear, owing inconclusive results a multicenter study this population. More research necessary determine combinations third- later-line settings. However, clearly provides significant clinical benefits On basis these addition its approval first-line setting, intravenous 5-fluorouracil-based chemotherapy recently received US Food Drug Administration